Anika Therapeutics (NASDAQ:ANIK) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Anika Therapeutics (NASDAQ:ANIK) posted its quarterly earnings data on Friday. The biotechnology company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.13), FiscalAI reports. Anika Therapeutics had a positive return on equity of 0.20% and a negative net margin of 3.14%. The company had revenue of $30.59 million for the quarter, compared to the consensus estimate of $29.44 million.

Here are the key takeaways from Anika Therapeutics’ conference call:

• Revenue rose 10% to $30.6 million, with commercial revenue up 17% to a record $14 million and OEM revenue up 5%. Integrity grew more than 30% year over year, while international OA pain management revenue increased 19%.
• Anika raised its 2026 total revenue growth outlook to 6%–10% from 5%–10% and its adjusted EBITDA margin outlook to 15%–17% from 13%–17%. The outlook reflects stronger expected OEM growth, partly offset by a lower commercial growth range amid slower summer elective procedures.
• Gross margin improved to 62% from 56% a year ago, and adjusted EBITDA increased to $5.1 million from $0.9 million. The company generated $8.4 million in quarterly operating cash and ended September with $45 million in cash.
• Anika signed a new 10-year Hyvisc distribution agreement that includes higher transfer pricing, royalties, increased minimum purchases, and $8 million in upfront and volume-based payments. The $4 million upfront payment is expected in the first quarter of 2027.
• The FDA notified Anika that the Hyalofast U.S. PMA is not approvable, primarily because of the clinical data submitted; the company is evaluating regulatory pathways and potential additional evidence requirements. Separately, Anika expects to submit the Cingal NDA before the end of 2027, following completion of bioequivalence-study enrollment and ongoing CMC work.

Anika Therapeutics Price Performance

Anika Therapeutics stock traded down $4.78 during mid-day trading on Friday, hitting $14.55. The company’s stock had a trading volume of 294,030 shares, compared to its average volume of 113,114. The stock has a market cap of $194.72 million, a price-to-earnings ratio of -53.89, a price-to-earnings-growth ratio of 14.57 and a beta of 0.21. The business has a 50 day moving average price of $20.51 and a 200-day moving average price of $16.23. Anika Therapeutics has a 12 month low of $9.01 and a 12 month high of $22.88.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Zacks Research downgraded Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anika Therapeutics in a report on Monday, September 21st. Wall Street Zen upgraded Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Barrington Research set a $21.00 price objective on Anika Therapeutics in a research report on Thursday, July 30th. Finally, B. Riley Financial assumed coverage on Anika Therapeutics in a report on Friday, September 18th. They set a “buy” rating and a $23.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $22.00.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.

Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.